一种具有强免疫原性和持续病毒学抑制作用的治疗性乙型肝炎信使核糖核酸疫苗。
A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression.
作者信息
Zhao Huajun, Shao Xianyu, Yu Yating, Huang Lulu, Amor Narh Philip, Guo Kun, Weng Changzhen, Zhao Weijun, Yang Ailu, Hu Jiesen, Yang Hongbao, Liu Zhenguang, Han Qiuju, Shi Leilei, Sun Shiyu, Zhang Jian, Lin Ang, Yang Yong
机构信息
Institute of Immunopharmaceutical Sciences, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Shandong University, Jinan, Shandong, China.
Vaccine Center, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
出版信息
NPJ Vaccines. 2024 Feb 3;9(1):22. doi: 10.1038/s41541-024-00813-3.
Here we report on the development and comprehensive evaluations of an mRNA vaccine for chronic hepatitis B (CHB) treatment. In two different HBV carrier mouse models generated by viral vector-mediated HBV transfection (pAAV-HBV1.2 and rAAV8-HBV1.3), this vaccine demonstrates sufficient and persistent virological suppression, and robust immunogenicity in terms of induction of strong innate immune activation, high-level virus-specific antibodies, memory B cells and T cells. mRNA platform therefore holds prospects for therapeutic vaccine development to combat CHB.
在此，我们报告一种用于慢性乙型肝炎（CHB）治疗的mRNA疫苗的研发及全面评估。在通过病毒载体介导的HBV转染产生的两种不同的HBV携带小鼠模型（pAAV-HBV1.2和rAAV8-HBV1.3）中，该疫苗表现出足够且持久的病毒学抑制作用，以及在诱导强烈的先天免疫激活、高水平病毒特异性抗体、记忆B细胞和T细胞方面强大的免疫原性。因此，mRNA平台在开发对抗CHB的治疗性疫苗方面具有前景。
Zotero 插件